Extracellular deposition of the (3/A4 amyloid peptide is a characteristic feature of the brain in patients with Alzheimer disease. ,f/A4 amyloid is derived from the amyloid precursor protein (APP), an integral membrane protein that exists as three major isoforms (APP695, APP75l, and APP770).
Secreted forms of APP found in blood plasma and cerebrospinal fluid arise by proteolytic cleavage of APP within the 13/A4 amyloid domain, precluding the possibility of amyloidogenesis for that population of molecules. In the present study, we have demonstrated that treatment of PC12 cells with phorbol ester produces a severalfold increase in secretion of APP6s, APP751, and APP770. This increase is augmented by simultaneous treatment with the protein phosphatase inhibitor okadaic acid. These data indicate that protein phosphorylation regulates intra-3/A4 amyloid cleavage and APP secretion. These and other results suggest that APP molecules can normally follow either of two processing pathways: regulated secretion or proteolytic degradation unassociated with secretion.
A characteristic pathological feature of Alzheimer disease is the extracellular deposition of 8/A4 amyloid in parenchymal brain tissues and in the walls of cerebral and meningeal blood vessels (1) (2) (3) . This -4-kDa peptide is derived from the amyloid precursor protein (APP), a transmembrane glycoprotein that exists as three major isoforms (APP695, APP751, and APP770; Fig. 1 A) , which result from the alternative splicing of mRNA from a single gene (4) (5) (6) (7) (8) (9) (10) . The larger APP751 and APP770 isoforms contain a Kunitz-type protease inhibitor (KPI) insert in their extracellular domains (8) (9) (10) . Secreted amino-terminal fragments of APP have been found in blood plasma and cerebrospinal fluid (11) (12) (13) . These secreted fragments result from cleavage of APP within the ,f/A4 amyloid domain (14, 15) . The process of APP secretion, therefore, precludes the cerebral amyloidogenesis associated with Alzheimer disease. We have previously demonstrated that activation of protein kinase C (PKC) in PC12 cells by treatment with phorbol ester results in more rapid intracellular turnover of APP and increased production of carboxylterminal APP fragments (16) . In the present report, we describe the regulation by protein phosphorylation of APP secretion in PC12 cells.
MATERIALS AND METHODS
The materials and methods used in this report, including the [35S]methionine pulse-chase procedure, have been reported (17) . PDBu, 4a-PDBu, and okadaic acid were purchased from LC Services (Woburn, MA). When the effects of phorbol esters (1 ,uM) 1B, lane 2 ). An antibody raised against unglycosylated APP695 produced in E. coli was found to immunoprecipitate mainly the 106-, 112-, and 116-kDa proteins (Fig. 1B, lane 5) .
In addition, antibody 369A, but not the other antibodies, immunoprecipitated a 16.3-kDa peptide (data not shown), which was found by radiosequence analysis to be the carboxyl-terminal fragment resulting from normal intra-P/A4 amyloid cleavage of APP (15) (Fig. 3) .
Effect of Phorbol Ester on APP Secretion. As phorbol esters were found to cause an increase in mature APP turnover, we examined whether this effect was associated with an alteration in the rate and/or amount of APP secretion. In the present study, PDBu treatment caused a dramatic increase in APP secretion (Fig. 4) . When the amounts of secreted APP were quantitated, the relative phorbol ester effects were approximately the same among APP isoforms (Fig. 5) There was a 3-fold accumulation of secreted APP in the medium of PDBu-treated cells relative to control levels. Phorbol ester caused an increase in the rate of accumulation and in the absolute amount of secreted APP. At 4 h of chase, =14% of the labeled APP present at the start of chase was recovered as secreted amino-terminal APP fragments from the medium of control cells, whereas =43% was recovered from the medium of PDBu-treated cells. This indicates that under control conditions, a relatively small pool of APP was cleaved within the f3/A4 amyloid domain to produce secreted APP. The majority of APP molecules were presumably degraded by an intracellular proteolytic pathway unassociated with secretion (17) .
When the difference between mature APP holoprotein recovered from PDBu-treated and untreated cells (at 30 min of chase) was compared to the difference between secreted APP fragments recovered from the medium of PDBu-treated and untreated cells (at 4 h of chase), a close correlation was found (27 ± 6 versus 31 ± 3 relative units, respectively). Thus, the phorbol ester-stimulated turnover of mature APP Proc. Natl. Acad Sci. USA 89 (1992) Proc. Natl. Acad. Sci. USA 89 (1992) holoprotein could be quantitatively accounted for by enhanced APP secretion.
Absence of Effect of Inactive Phorbol Ester on APP Secretion. As a control for the specificity of PDBu activation of PKC, cells were also treated with the inactive analogue, 4a-PDBu. There was virtually no effect on APP maturation or holoprotein turnover (data not shown) or on APP secretion (Fig. 6 ) in the presence of 4a-PDBu relative to cells treated with vehicle alone.
Effect of Combined Treatment with Phorbol Ester and Okadaic Acid on APP Secretion. Combined treatment with PDBu and okadaic acid, an inhibitor of protein phosphatases 1 and 2A, was previously found to increase recovery of APP carboxyl-terminal fragments (16) . Therefore, we examined the effect of combined treatment on APP secretion (Fig. 7) . Cells treated for 1 h with okadaic acid alone secreted more APP than untreated cells but less APP than cells treated with PDBu. When cells were treated with both PDBu and okadaic acid, APP secretion at 1 h was greater than APP secretion in cells treated with PDBu or okadaic acid alone.
Although combined treatment with PDBu and okadaic acid produces a carboxyl-terminal fragment that migrates on SDS/polyacrylamide gels more slowly than the 16.3-kDa species (16) , no evidence of truncated secreted APP fragments was found. Furthermore, no treatments resulted in the detection of cleaved amino-terminal APP fragments in cell lysates. 
DISCUSSION
We have demonstrated in PC12 cells that, under basal conditions, a relatively small pool of APP was cleaved within the f3/A4 amyloid domain to produce secreted APP, indicating that the majority of APP molecules was degraded by a proteolytic pathway unassociated with secretion. The intra-,B/A4 amyloid cleavage and secretion of amino-terminal APP fragments were stimulated severalfold by PDBu treatment, presumably by the activation of PKC. These data provide a possible mechanism for regulation of APP function.
Regulation by PKC of the conversion of integral proteins from membrane-bound to soluble forms with a subsequent alteration in their function has been reported for tumor necrosis factor receptor (19) , colony-stimulating factor 1 receptor (20) , murine neutrophil MEL-14 antigen (21), and pro-transforming growth factor a (22) . On the basis of the resemblance of the APP topology to that of certain cellsurface receptors, APP was postulated to function as a cell-surface binding protein for an as yet unidentified ligand Results are the mean + SEM of four experiments (n = 2 to 4 for individual time points). There was no statistical significance between untreated and treated samples for any time points as determined by Student's unpaired t test.
(5), an interpretation supported by the localization of some APP molecules to the plasma membrane (11) . Regulated proteolytic cleavage and secretion of APP by activation of PKC could serve two purposes: down-regulation ofAPP from the cell surface and release of a functional APP fragment into the surrounding environment (23 (24, 25) , a soluble protein that forms complexes with epidermal growth factor-binding protein, the y subunit of nerve growth factor, and trypsin (26) . The physiological significance of these interactions is not understood, but protease nexin II released from platelets has been found to be a potent inhibitor of coagulation factor XIa (27) .
We have not yet determined whether the phorbol esterinduced effects on APP secretion are due to phosphorylation of APP by PKC ("substrate activation"), activation of an APP "secretase" ("enzyme activation"), or redirected cellular trafficking that brings APP in contact with its protease(s) (23) . Support for the "substrate activation" model comes from studies in our laboratory demonstrating that PKC can phosphorylate synthetic APP carboxyl-terminal peptides (28) and from other studies that demonstrate that mature APP is phosphorylated in cultures of intact cells (29) . In a system that might be analogous, phosphorylation of the polymeric immunoglobulin receptor results in acceleration of its transcytosis and proteolytic cleavage to produce secretory component (30) . The "enzyme activation" model is supported by studies on the colony-stimulating factor 1 receptor, in which PKC has been suggested to act on the protease responsible for the release of soluble receptor rather than on the membrane-bound receptor itself (20) .
The majority of APP molecules are degraded in unstimulated PC12 cells by a chloroquine-sensitive endosomal/ lysosomal proteolytic pathway; a small fraction undergoes intra-(3/A4 amyloid cleavage by a chloroquine-insensitive pathway to produce secreted amino-terminal APP fragments and a 16.3-kDa carboxyl-terminal APP fragment (17) . These earlier observations, combined with the results of the present report, suggest a scheme for the cellular trafficking and proteolytic processing of APP (Fig. 8) 
